Napabucasin Failure Costly, And Possibly Transformative, For Dainippon
Latuda Expiry Also Looming
Executive Summary
Japanese firm’s recent decision to halt development of its lead oncology asset, gained through a multi-billion-dollar acquisition where it was the main attraction, not only has a financial cost but may prompt more strategic deal-making.